Innovation

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.

Johnson & Johnson is restoring the true meaning of healthcare by developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases.

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.

If you can’t read a screen without jacking up the brightness level or if night driving leaves you seeing fuzzy halos around traffic lights, you may among the 20 million U.S. adults who develops a cataract—the most common cause of vision loss worldwide. Luckily a simple surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.

Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.

Meet Xiao-Yu Song, Global Head of Research & Development for Vision at Johnson & Johnson, who leads a talented team that creates cutting-edge products addressing vision problems through all stages of life.